MindWalk Holdings posts 21% revenue growth and expands gross margins to 59%, bolstered by a new $30 million credit facility to accelerate enterprise adoption of its ReefIQ AI drug discovery platform.
MindWalk reported 21% revenue growth, expanding gross margins, and a new credit facility, signaling strong commercial momentum and platform adoption.
MindWalk Holdings reported a 21% year-over-year revenue increase for fiscal Q1 2027, driven by strong platform adoption. The company also secured a $30 million unsecured revolving credit facility to fund growth without equity dilution, signaling management's confidence in its ReefIQ data platform and internal drug discovery pipeline.
The facility provides financial flexibility to invest in the ReefIQ platform and internal drug discovery pipeline without the need for equity issuance, which management believes is currently undervalued.